Graft-versus-Host Disease-Like Pattern in Mycophenolate Mofetil Related Colon Mucosal Injury: Role of FISH in Establishing the Diagnosis. by Behling, Kathryn C et al.
 Case Rep Gastroenterol  2009;3:418–423 
DOI:  10.1159/000260903 
Publ ished onl ine:  December  9,  2009 © 2009 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
Kathryn C. Behling, MD, PhD  Department of Pathology, 132 South 10th Street, 285 Main Building Philadelphia, PA 19107 (USA) 
Tel. +1 215 955 6352, Fax +1 215 923 1969 
E-Mail kathryn.behling@jeffersonhospital.org 
 
418
  
Graft-versus-Host Disease-Like 
Pattern in Mycophenolate 
Mofetil Related Colon Mucosal 
Injury: Role of FISH in 
Establishing the Diagnosis 
Kathryn C. Behling    Dorothy M.J. Foster    
Tina B. Edmonston    Agnieszka K. Witkiewicz 
Department of Pathology, Thomas Jefferson University, Philadelphia, Pa., USA 
 
Key Words 
Mycophenolate mofetil · Graft-versus-host disease · Fluorescence in situ hybridization · 
Heart transplantation · Colitis 
Abstract 
Mycophenolate mofetil (CellCept), a commonly used immunosuppressive drug in solid 
organ transplantation, has recently been shown to cause graft-versus-host disease 
(GVHD)-like changes in the gastrointestinal tract. On rare occasions, true GVHD has also 
been documented in the gastrointestinal tract of solid organ transplant patients. 
Because the treatment for these two entities is different, i.e. removal of the offending 
agent versus the administration of steroids, proper identification of the cause is 
imperative. We present a case of mycophenolate mofetil colitis mimicking grade I GVHD 
of the gut. In our study, we used fluorescence in situ hybridization for the Y chromosome 
to document the lack of male donor lymphocytes in the female recipient colon biopsy. 
We suggest that molecular techniques including fluorescence in situ hybridization could 
be used to discriminate between MMF-related colitis and true GVHD in order to help 
guide therapy. 
Introduction 
Mycophenolate mofetil (MMF), a commonly used immunosuppressive drug in solid 
organ transplantation, has resulted in a significant decrease in allograft rejection. MMF is 
an antimetabolite that inhibits inosine monophosphate dehydrogenase, resulting in 
blockade of the de novo pathway of purine synthesis. Because this pathway is exclusively 
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used by B and T lymphocytes for purine synthesis, MMF administration causes selective 
inhibition of lymphocyte proliferation [1]. Gastrointestinal side effects, including 
diarrhea, are common with MMF and are caused by specific (suppression of de novo 
purine synthesis) and nonspecific (immunosuppressive) effects of the drug on the 
gastrointestinal tract [1]. MMF-related colitis has many features in common with 
graft-versus-host disease (GVHD) colitis seen in patients who have undergone allogeneic 
bone marrow transplantation, including crypt architectural disarray, gland distortion 
with lamina propria fibrosis and edema, increased lamina propria inflammation, and 
increased crypt epithelial apoptosis [2–4]. Some have also found enterocyte atypia, 
increased neuroendocrine cells, and microvascular injury [2, 3]. We report a case of colitis 
with features consistent with both MMF colitis and GVHD in a patient receiving MMF as 
part of an immunosuppressive regimen after heart transplantation. Because the recipient 
was female and the donor was male, we used fluorescence in situ hybridization (FISH) for 
the Y chromosome to determine the origin of the lymphocytes present within the colon 
biopsy. The presence or absence of donor lymphocytes in colonic lesions in conjunction 
with clinical data could help to determine the cause of the patient’s colitis and guide 
treatment. 
Case Report 
The patient was a 69-year-old woman with a past medical history significant for osteopenia, chronic 
lower back pain and diverticulosis who presented with weakness and fatigue for approximately one 
month accompanied by low blood pressure (70/40 mm Hg) and mild shortness of breath. The patient 
had a history of a left heart catheterization in 2007 which showed dilated nonischemic cardiomyopathy 
with an ejection fraction of approximately 30%. On the last admission prior to transplantation, the 
patient was hypotensive and had an ejection fraction of 15%. She was started on dobutamine, and an 
implantable cardioverter-defibrillator device was placed. The patient was ultimately maintained on 
milrinone and evaluated for orthotopic heart transplantation. 
Once a heart became available for transplantation, the patient was started on prednisone, MMF, and 
tacrolimus. A heart from a male donor was transplanted without complication. The explanted heart 
showed dilated cardiomyopathy with cardiomyopathy of end-stage heart failure. The patient’s 
postoperative course was complicated by an upper extremity deep venous thrombosis for which the 
patient received enoxaparin 60 mg subcutaneous every 12 h. The patient was discharged to home on 
postoperative day eight on valgancyclovir, pravastatin, iron sulfate, enoxaparin, nystatin, diltiazem-SR, 
Bactrim-DS, aspirin, lexapro, and an immunosuppressive regimen including tacrolimus 4 mg every 
12 h, a prednisone taper, and MMF 750 mg every 12 h. 
Two months after transplantation, the patient presented with a two-week history of watery stools 
and diarrhea consisting of four to five episodes after each meal with occasional maroon blood in the 
stool. These episodes were preceded by cramping, nonradiating abdominal pain and were not 
accompanied by fevers, chills, nausea, vomiting, hematemesis, melena, chest pain, shortness of breath, 
dizziness, palpitations, dysuria, or hematuria. She had a history of hemorrhoids and diverticulitis in the 
past and had also had a recent colonoscopy which was negative. There was no history of NSAID use or 
peptic ulcer disease. Microscopic studies of her stool were negative for Giardia lamblia, Entamoeba 
histolytica, ova and parasites, Salmonella spp., Shigella spp., Cryptosporidium, Campylobacter spp., as 
well as C. difficile toxin and antigen and Rotatvirus antigen. There was no increase in white blood cells 
in the stool. The stool was Hemoccult-positive. An abdominal X-ray demonstrated no intestinal 
obstruction. A colonoscopy performed at this time showed severe diverticulosis, and biopsies revealed 
colonic mucosa with crypt apoptosis, lamina propria fibrosis, and inflammatory cell infiltrate which 
could be consistent with GVHD. No evidence of cytomegalovirus was identified. The patient was 
treated with three days of outpatient steroids. Her MMF was held prior to discharge due to leukopenia. 
The patient was readmitted three days later with bloody, Hemoccult-positive stools. Colonoscopy 
and esophagogastroduodenoscopy failed to demonstrate a source of bleeding. It was felt that the 
patient’s symptoms, including bleeding and bloating, were due to MMF, and her immunosuppressive 
regimen was change to tacrolimus and azathioprine with amelioration of her gastrointestinal symptoms. 
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FISH for the X and Y chromosome was performed on paraffin-embedded tissue prepared in the 
histology lab at Thomas Jefferson University Hospital. The slides were subjected to deparaffinization 
using Hemo-D (three washes, 10 min each) and 100% ethanol (two washes, 5 min each). The slides were 
pretreated as follows: 0.2 N HCl for 20 min at room temperature followed by a wash in 2× SSC for 3 min 
at room temperature; 2× SSC at 73°C for 30 min; 30% pepsin in 2× SSC for 30 min at 45°C followed by a 
wash in 2× SSC for 3 min at room temperature; proteinase K for 20 min at 45°C followed by a wash in 
2× SSC for 3 min at room temperature. The slides were postfixed in 10% formalin for 10 min at room 
temperature and washed in 2× SSC for 3 min at room temperature. The slides were dehydrated and 
denatured and prepared for hybridization with CEP X and CEP Y Dual color probe (1:10 dilution) 
(Vysis, Des Plaines, Ill., USA) overnight at 37°C. The slides were washed in posthybridization buffer for 
2 min at 72°C and counterstained with 4c,6-diamidino-2-phenylindole.  
Microscopic examination of the random colon biopsies revealed colonic mucosa with areas of crypt 
apoptosis and lamina propria fibrosis (fig. 1). There was a mixed inflammatory cell infiltrate 
predominately composed of mature lymphocytes. No viral inclusions were identified, and a special 
immunohistochemcial stain for cytomegalovirus was negative (data not shown). 
Because the patient was female and the donor was male, FISH was performed to detect the presence 
of the Y chromosome in lymphocytes present in the biopsy material. Gender-mismatched 
transplantations, in which a female patient receives a male donor organ, offer a unique opportunity to 
investigate recipient tissues, because the detection of the Y chromosome discriminates the cells of donor 
origin from recipient-derived cells. No Y chromosome signals were detected, indicating there was no 
significant infiltrate by cells derived from the male heart donor (fig. 1). 
Discussion 
MMF, a commonly used immunosuppressive drug for solid organ transplantation, has 
resulted in a dramatic decrease in graft rejection. MMF acts by inhibiting inosine 
monophosphate dehydrogenase resulting in selective inhibition of the de novo pathway 
for purine synthesis. Purine synthesis can occur via the de novo and/or the salvage 
pathway in most cells. However, lymphocytes are unique in that they almost exclusively 
use the de novo pathway. Therefore, administration of MMF results in selective inhibition 
of lymphocyte proliferation [1]. 
Gastrointestinal side effects are common with MMF administration. These effects are 
due to specific and nonspecific effects of MMF on the gastrointestinal tract. One 
nonspecific effect is increased immunosuppression leading to increased susceptibility of 
the gastrointestinal mucosa to infection by microorganisms and viruses. Increased 
immunosuppression does not increase susceptibility to any single organism but results in 
more likely infection with less pathogenic organisms as well as increased symptomatology 
in cases where infections may have remained subclinical [1]. 
MMF also has specific effects on enterocytes. These cells are approximately 50% 
dependent on the de novo pathway for purine synthesis. Because enterocytes have a high 
turnover rate, inhibition of proliferation by MMF can have a dramatic effect on mucosal 
integrity. Interestingly, after administration, the highest concentrations of MMF have 
been found in the gastrointestinal tract, which may exacerbate the effect of MMF on these 
cells [1]. 
There is some evidence that in lymphocytes, with increasing exposure to MMF there is 
induction of inosine monophosphate dehydrogenase expression which may counteract 
the effects of MMF. Some feel that this may also occur in enterocytes which may explain 
the decrease in additional incidence of gastrointestinal side effects after 6 months of MMF 
usage [1]. 
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There has been limited examination of the histologic findings associated with 
MMF-related colitis with several groups reporting GVHD-like histology [2–4]. In one 
study, MMF colitis showed a significant difference in crypt cell apoptosis, gland 
distortion, epithelial cell atypia, the number of neuroendocrine cells, and lamina propria 
inflammation as compared to matched controls. This morphology significantly overlaps 
with that seen in GVHD [2]. A later study demonstrated that despite the overlap in 
histologic features, certain findings such as crypt cell apoptosis and the number of 
apoptotic cells were increased with GVHD as compared to MMF exposure. This study 
also found that mucosal architectural disarray, epithelial cell atypia, lamina propria 
inflammation, number of intraepithelial lymphocytes, number of neuroendocrine cells, 
mononuclear cell apoptosis, and microvascular injury were also increased in both patients 
with GVHD and those exposed to MMF as compared to controls [3]. A recent study 
showed that in patients exposed to MMF, GVHD-like histology can be seen throughout 
the gastrointestinal tract including the stomach and esophagus [5]. 
Some may argue that the histologic findings that some are attributing to MMF toxicity 
may actually be due to GVHD. As opposed to bone marrow transplantation, GVHD is 
uncommon in solid organ transplantation [6–8]. Billingham [9] suggested that three 
criteria must be met in order for GVHD to occur: (1) presence of HLA differences 
between the host and donor, (2) presence of immunocompetent donor cells, and 
(3) suppression of the host immune system. These criteria are easily met in bone marrow 
transplants that are not HLA-matched since a competent immune system is transplanted 
along with other marrow elements necessary for effective hematopoiesis. In solid organ 
transplantation, a small number of immunocompetent cells are present in transplanted 
organs. Also, due to logistical concerns, the organs are often not HLA-matched. Some 
solid organs carry more lymphoid tissue, which explains the larger number of reported 
cases of GVHD in liver, small bowel, and heart-lung as opposed to kidney and heart 
transplantations [6, 7]. Immunocompetent cells within the donor organ migrate into host 
tissues relatively quickly after transplantation. GVHD in these cases usually occurs 1–12 
weeks after transplantation [6]. The presence of donor lymphocytes has been documented 
in recipient tissue using HLA antibodies and short tandem repeat analysis [6–8]. The 
presence of these lymphocytes has correlated with the presence of GVHD in these 
recipients [6–8]. 
In the current case, the patient began to experience diarrhea approximately 8 weeks 
after transplantation. Infectious etiologies were ruled out, and a colon biopsy 
demonstrated findings consistent with grade 1 GVHD. Because the recipient was female 
and the donor was male, we were able to determine the origin of lymphocytes present 
within the colon biopsy using a probe for the Y chromosome. We decided against using 
short tandem repeat analysis, which is commonly employed for bone marrow 
engraftment studies, because the colon biopsy was paraffin-embedded, which would have 
reduced our ability to adequately amplify DNA present within the biopsy. Examination of 
the peripheral blood for donor lymphocytes was not performed due to the unavailability 
of this specimen at the time of our study. Ultimately, we showed that there was no 
significant donor lymphocyte infiltrate in the recipient colon biopsy. This finding 
together with the improvement of the patient’s symptoms subsequent to removal of MMF 
from the patient’s immunosuppressive regimen suggest that MMF toxicity, as opposed to 
GVHD, was the cause of the patient’s colitis. Although the patient was also administered 
steroids subsequent to the colon biopsy for possible GVHD, we feel that given the lack of 
donor lymphocytes in the colon biopsy, the rapid improvement in symptoms subsequent 
to MMF withdrawal, and the rarity of GVHD in heart transplantation, MMF toxicity is a 
much more likely cause of the patient’s symptomatology. 
 Case Rep Gastroenterol  2009;3:418–423 
DOI:  10.1159/000260903 
Publ ished onl ine:  December  9,  2009 © 2009 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
422
In the current case, we found that there is substantial overlap between the histologic 
findings present in GVHD and MMF-related colitis. Molecular techniques, including 
FISH where appropriate, can be employed to demonstrate the presence or absence of 
donor lymphocytes. Molecular findings properly correlated with clinical and morphologic 
findings can help direct therapy which may include withdrawal of the offending agent, in 
the case of MMF-related colitis, or administration of steroids, in the case of GVHD. 
 
 
 
 
 
Fig. 1. GVHD-like histology in MMF toxicity of the colon. a There is a mixed inflammatory infiltrate 
composed primarily of mature lymphocytes and eosinophils. The arrow indicates an apoptotic 
enterocyte within a crypt. The inset shows a higher magnification of a crypt with an apoptotic 
enterocyte (hematoxylin-eosin, original magnifications 200× (inset 400×)). b FISH for detection of the 
X (red) and Y (green) chromosome (XX/XY) in lymphocytes of the lamina propria. Only the 
X chromosome is detected in lymphocytes of the lamina propria in this specimen. 
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